Cost‐Effectiveness of Control‐ IQ + Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States
Authors' conclusion
Control-IQ+ is associated with increased life expectancy, higher QALYs and reduced complication rates.
Study context
- Population
- Adults with insulin-treated T2D, United States
- Comparison
- T:slim X2 insulin pump with Control-IQ+ technology vs MDI/CGM
- Outcome
- Incremental cost-effectiveness ratio (cost per QALY)
- Follow-up
- 50 years
Methodological detailsIQVIA CORE Diabetes Model v10.0 simulation, 50-year time horizon, based on 2IQP RCT data, probabilistic sensitivity analyses, scenario analyses
- IQVIA CORE Diabetes Model v10.0 simulation
- 50-year time horizon
- Based on 2IQP RCT data
- Probabilistic sensitivity analyses
- Scenario analyses
Main finding
As reported in the abstract
Direct medical costs, QALYs and ICER
Additional QALYs
0.51 QALYs
Direct medical costs, QALYs and incremental cost-effectiveness ratio (ICER)
ICER
$59 417 per QALY
95% CI $55 836, $62 998
base case
Control-IQ+
$239 935
direct medical costs per individual
MDI/CGM
$209 792
direct medical costs per individual
Further findings
Probabilistic sensitivity analyses
- Simulations producing ICERs below $100 000/QALY
- 89%
Scenario analyses
- ICERs across all scenarios remained below $100 000 per QALY
Original publication
Cost‐Effectiveness of Control‐ IQ + Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States. Diabetes Obes Metab. Published 5 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →